Logo
x

Search

Subscribe Now

All Posts by Date

Eisai and Biogen Publishes Results of P-III Study (Clarity AD) of Lecanemab for Early Alzheimer's Disease

Eisai and Biogen Publishes Results of P-III Study (Clarity AD) of Lecanemab for Early Alzheimer's Disease

  • November 30, 2022
Priya Singhal, Senior Vice President at Biogen, Shares Insights from Litifilimab Systemic Lupus Erythematosus NEJM Publication

Priya Singhal, Senior Vice President at Biogen, Shares Insights from Litifilimab Systemic Lupus Erythematosus NEJM Publication

  • November 30, 2022
Shanghai Henlius Biotech Reports First Patient Dosing of Hansizhuang for Extensive-Stage Small Cell Lung Cancer Treatment in the US

Shanghai Henlius Biotech Reports First Patient Dosing of Hansizhuang for Extensive-Stage Small Cell Lung Cancer Treatment in the U...

  • November 30, 2022
Turnstone Biologics and National Cancer Institute Enters into a R&D Agreement to Study TIL Therapy + Viral Immunotherapy for Solid Tumors

Turnstone Biologics and National Cancer Institute Enters into a R&D Agreement to Study TIL Therapy + Viral Immunotherapy for Solid...

  • November 30, 2022
Autobahn Initiates the P-I Trial of ABX-002 for the Treatment of Major Depressive Disorder

Autobahn Initiates the P-I Trial of ABX-002 for the Treatment of Major Depressive Disorder

  • November 30, 2022
Aclaris Enters into a License Agreement with Pediatrix for Developing and Commercializing ATI-1777 in Greater China

Aclaris Enters into a License Agreement with Pediatrix for Developing and Commercializing ATI-1777 in Greater China

  • November 30, 2022
Image

Stay Connected

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.